OSA Initiates Histone Lactylation That Drives PDE4B/FUS/AGT Axis to Pulmonary Hypertension

Abstract

Obstructive sleep apnea (OSA) is strongly associated with an increased risk of hypertension; however, the molecular mechanisms linking these two conditions remain incompletely understood. In this study, we identified phosphodiesterase 4B (PDE4B) as a key mediator in the development of OSA-related hypertension. Using integrated bioinformatics analysis and experimental validation, we found that PDE4B expression was significantly elevated in both cell and animal models of OSA combined with pulmonary hypertension. Functional studies demonstrated that PDE4B promotes pulmonary artery smooth muscle cell (PASMC) proliferation and migration, contributing to vascular remodelling. Mechanistically, we uncovered that lactate accumulation under hypoxic conditions induces histone lactylation at the PDE4B promoter, enhancing its transcriptional activity. Furthermore, PDE4B was shown to regulate the phosphorylation and nuclear translocation of FUS, which binds to the angiotensinogen (AGT) promoter and enhances AGT expression, thereby promoting pulmonary hypertension. These findings reveal a novel PDE4B-FUS-AGT signalling axis driven by epigenetic modifications in OSA-induced hypertension, offering potential therapeutic targets for patients with this comorbidity.

Keywords

histone lactylation / OSA-related hypertension / oxidative stress / PASMC remodelling / PDE4B

References

[1] D. J. Gottlieb and N. M. Punjabi, “Diagnosis and Management of Obstructive Sleep Apnea: A Review,” JAMA 323, no. 14 (2020): 1389–1400, https://doi.org/10.1001/jama.2020.3514.

[2] Y. Adir, M. Humbert, and A. Chaouat, “Sleep-Related Breathing Disorders and Pulmonary Hypertension,” European Respiratory Journal 57, no. 1 (2021): 2002258, https://doi.org/10.1183/13993003.02258-2020.

[3] S. Redline, A. Azarbarzin, and Y. Peker, “Obstructive Sleep Apnoea Heterogeneity and Cardiovascular Disease,” Nature Reviews. Cardiology 20, no. 8 (2023): 560–573, https://doi.org/10.1038/s41569-023-00846-6.

[4] M. L. Cabrini, T. A. Macedo, E. Castro, et al., “Obstructive Sleep Apnea and Hypertension-Mediated Organ Damage in Nonresistant and Resistant Hypertension,” Hypertension Research 46, no. 8 (2023): 2033–2043, https://doi.org/10.1038/s41440-023-01320-z.

[5] N. R. Prabhakar, Y. J. Peng, and J. Nanduri, “Hypoxia-Inducible Factors and Obstructive Sleep Apnea,” Journal of Clinical Investigation 130, no. 10 (2020): 5042–5051, https://doi.org/10.1172/JCI137560.

[6] R. Dumitrascu, J. Heitmann, W. Seeger, N. Weissmann, and R. Schulz, “Obstructive Sleep Apnea, Oxidative Stress and Cardiovascular Disease: Lessons From Animal Studies,” Oxidative Medicine and Cellular Longevity 2013 (2013): 234631, https://doi.org/10.1155/2013/234631.

[7] E. Vicente, J. M. Marin, S. J. Carrizo, et al., “Upper Airway and Systemic Inflammation in Obstructive Sleep Apnoea,” European Respiratory Journal 48, no. 4 (2016): 1108–1117, https://doi.org/10.1183/13993003.00234-2016.

[8] D. A. Butterfield and B. Halliwell, “Oxidative Stress, Dysfunctional Glucose Metabolism and Alzheimer Disease,” Nature Reviews. Neuroscience 20, no. 3 (2019): 148–160, https://doi.org/10.1038/s41583-019-0132-6.

[9] Y. Zhang, H. Song, M. Li, and P. Lu, “Histone Lactylation Bridges Metabolic Reprogramming and Epigenetic Rewiring in Driving Carcinogenesis: Oncometabolite Fuels Oncogenic Transcription,” Clinical and Translational Medicine 14, no. 3 (2024): e1614, https://doi.org/10.1002/ctm2.1614.

[10] K. Xu, K. Zhang, Y. Wang, and Y. Gu, “Comprehensive Review of Histone Lactylation: Structure, Function, and Therapeutic Targets,” Biochemical Pharmacology 225 (2024): 116331, https://doi.org/10.1016/j.bcp.2024.116331.

[11] J. Chen, M. Zhang, Y. Liu, et al., “Histone Lactylation Driven by mROS-Mediated Glycolytic Shift Promotes Hypoxic Pulmonary Hypertension,” Journal of Molecular Cell Biology 14, no. 12 (2023): mjac073, https://doi.org/10.1093/jmcb/mjac073.

[12] S. S. Zhao, J. Liu, Q. C. Wu, and X. L. Zhou, “Role of Histone Lactylation Interference RNA m(6)A Modification and Immune Microenvironment Homeostasis in Pulmonary Arterial Hypertension,” Frontiers in Cell and Developmental Biology 11 (2023): 1268646, https://doi.org/10.3389/fcell.2023.1268646.

[13] S. A. Myers, L. Gobejishvili, S. Saraswat Ohri, et al., “Following Spinal Cord Injury, PDE4B Drives an Acute, Local Inflammatory Response and a Chronic, Systemic Response Exacerbated by Gut Dysbiosis and Endotoxemia,” Neurobiology of Disease 124 (2019): 353–363, https://doi.org/10.1016/j.nbd.2018.12.008.

[14] Z. Pan, X. Wu, X. Zhang, and K. Hu, “Phosphodiesterase 4B Activation Exacerbates Pulmonary Hypertension Induced by Intermittent Hypoxia by Regulating Mitochondrial Injury and cAMP/PKA/p-CREB/PGC-1alpha Signaling,” Biomedicine & Pharmacotherapy 158 (2023): 114095, https://doi.org/10.1016/j.biopha.2022.114095.

[15] Y. Xing, Y. Hou, T. Fan, et al., “Endothelial Phosphodiesterase 4B Inactivation Ameliorates Endothelial-To-Mesenchymal Transition and Pulmonary Hypertension,” Acta Pharmaceutica Sinica B 14, no. 4 (2024): 1726–1741, https://doi.org/10.1016/j.apsb.2024.01.012.

[16] Q. Zhang, J. Liu, H. Duan, R. Li, W. Peng, and C. Wu, “Activation of Nrf2/HO-1 Signaling: An Important Molecular Mechanism of Herbal Medicine in the Treatment of Atherosclerosis via the Protection of Vascular Endothelial Cells From Oxidative Stress,” Journal of Advanced Research 34 (2021): 43–63, https://doi.org/10.1016/j.jare.2021.06.023.

[17] P. Diaz-Vivancos, A. de Simone, G. Kiddle, and C. H. Foyer, “Glutathione-Linking Cell Proliferation to Oxidative Stress,” Free Radical Biology and Medicine 89 (2015): 1154–1164, https://doi.org/10.1016/j.freeradbiomed.2015.09.023.

[18] P. Lee, N. S. Chandel, and M. C. Simon, “Cellular Adaptation to Hypoxia Through Hypoxia Inducible Factors and Beyond,” Nature Reviews. Molecular Cell Biology 21, no. 5 (2020): 268–283, https://doi.org/10.1038/s41580-020-0227-y.

[19] H. Rho, A. R. Terry, C. Chronis, and N. Hay, “Hexokinase 2-Mediated Gene Expression via Histone Lactylation Is Required for Hepatic Stellate Cell Activation and Liver Fibrosis,” Cell Metabolism 35, no. 8 (2023): 1406–1423.e8, https://doi.org/10.1016/j.cmet.2023.06.013.

[20] D. Zhang, Z. Tang, H. Huang, et al., “Metabolic Regulation of Gene Expression by Histone Lactylation,” Nature 574, no. 7779 (2019): 575–580, https://doi.org/10.1038/s41586-019-1678-1.

[21] C. Wang, S. Wang, Z. Wang, et al., “Andrographolide Regulates H3 Histone Lactylation by Interfering With p300 to Alleviate Aortic Valve Calcification,” British Journal of Pharmacology 181, no. 12 (2024): 1843–1856, https://doi.org/10.1111/bph.16332.

[22] Y. Wei, B. Pan, J. Qin, et al., “The Walnut-Derived Peptide TW-7 Improves Mouse Parthenogenetic Embryo Development of Vitrified MII Oocytes Potentially by Promoting Histone Lactylation,” Journal of Animal Science and Biotechnology 15, no. 1 (2024): 86, https://doi.org/10.1186/s40104-024-01045-0.

[23] U. Makhmudova, E. Steinhagen-Thiessen, M. Volpe, and U. Landmesser, “Advances in Nucleic Acid-Targeted Therapies for Cardiovascular Disease Prevention,” Cardiovascular Research 120, no. 10 (2024): 1107–1125, https://doi.org/10.1093/cvr/cvae136.

[24] J. Lee and H. Kang, “Nucleolin Regulates Pulmonary Artery Smooth Muscle Cell Proliferation Under Hypoxia by Modulating miRNA Expression,” Cells 12, no. 5 (2023): 817, https://doi.org/10.3390/cells12050817.

[25] M. Sachse, S. Tual-Chalot, G. Ciliberti, et al., “RNA-Binding Proteins in Vascular Inflammation and Atherosclerosis,” Atherosclerosis 374 (2023): 55–73, https://doi.org/10.1016/j.atherosclerosis.2023.01.008.

[26] M. Kolb, B. Crestani, and T. M. Maher, “Phosphodiesterase 4B Inhibition: A Potential Novel Strategy for Treating Pulmonary Fibrosis,” European Respiratory Review 32, no. 167 (2023): 220206, https://doi.org/10.1183/16000617.0206-2022.

[27] L. Richeldi, A. Azuma, V. Cottin, et al., “Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis,” New England Journal of Medicine 386, no. 23 (2022): 2178–2187, https://doi.org/10.1056/NEJMoa2201737.

[28] S. Abid, E. Marcos, A. Parpaleix, et al., “CCR2/CCR5-Mediated Macrophage-Smooth Muscle Cell Crosstalk in Pulmonary Hypertension,” European Respiratory Journal 54, no. 4 (2019): 1802308, https://doi.org/10.1183/13993003.02308-2018.

[29] L. Hu, J. Wang, H. Huang, et al., “YTHDF1 Regulates Pulmonary Hypertension Through Translational Control of MAGED1,” American Journal of Respiratory and Critical Care Medicine 203, no. 9 (2021): 1158–1172, https://doi.org/10.1164/rccm.202009-3419OC.

[30] J. Ma, V. Kumar, and R. I. Mahato, “Nanoparticle Delivery of Novel PDE4B Inhibitor for the Treatment of Alcoholic Liver Disease,” Pharmaceutics 14, no. 9 (2022): 1894, https://doi.org/10.3390/pharmaceutics14091894.

[31] M. Schepers, D. Paes, A. Tiane, et al., “Selective PDE4 Subtype Inhibition Provides New Opportunities to Intervene in Neuroinflammatory Versus Myelin Damaging Hallmarks of Multiple Sclerosis,” Brain, Behavior, and Immunity 109 (2023): 1–22, https://doi.org/10.1016/j.bbi.2022.12.020.

[32] J. Foo, G. Bellot, S. Pervaiz, and S. Alonso, “Mitochondria-Mediated Oxidative Stress During Viral Infection,” Trends in Microbiology 30, no. 7 (2022): 679–692, https://doi.org/10.1016/j.tim.2021.12.011.

[33] E. Pick, “The Necessity of NEDD8/Rub1 for Vitality and Its Association With Mitochondria-Derived Oxidative Stress,” Redox Biology 37 (2020): 101765, https://doi.org/10.1016/j.redox.2020.101765.

[34] F. Li, W. Si, L. Xia, et al., “Positive Feedback Regulation Between Glycolysis and Histone Lactylation Drives Oncogenesis in Pancreatic Ductal Adenocarcinoma,” Molecular Cancer 23, no. 1 (2024): 90, https://doi.org/10.1186/s12943-024-02008-9.

[35] Y. Huang, C. Wang, T. Zhou, et al., “Lumican Promotes Calcific Aortic Valve Disease Through H3 Histone Lactylation,” European Heart Journal 45 (2024): 3871–3885, https://doi.org/10.1093/eurheartj/ehae407.

[36] K. D. Nguyen, V. Pihur, S. K. Ganesh, et al., “Effects of Rare and Common Blood Pressure Gene Variants on Essential Hypertension: Results From the Family Blood Pressure Program, CLUE, and Atherosclerosis Risk in Communities Studies,” Circulation Research 112, no. 2 (2013): 318–326, https://doi.org/10.1161/CIRCRESAHA.112.276725.

[37] F. Ye, Y. Wang, C. Wu, et al., “Angiotensinogen and Megalin Interactions Contribute to Atherosclerosis-Brief Report,” Arteriosclerosis, Thrombosis, and Vascular Biology 39, no. 2 (2019): 150–155, https://doi.org/10.1161/ATVBAHA.118.311817.

[38] M. Eriguchi, K. Tsuruya, N. Haruyama, et al., “Renal Denervation Has Blood Pressure-Independent Protective Effects on Kidney and Heart in a Rat Model of Chronic Kidney Disease,” Kidney International 87, no. 1 (2015): 116–127, https://doi.org/10.1038/ki.2014.220.

[39] B. Portz, B. L. Lee, and J. Shorter, “FUS and TDP-43 Phases in Health and Disease,” Trends in Biochemical Sciences 46, no. 7 (2021): 550–563, https://doi.org/10.1016/j.tibs.2020.12.005.

[40] N. Birsa, A. M. Ule, M. G. Garone, et al., “FUS-ALS Mutants Alter FMRP Phase Separation Equilibrium and Impair Protein Translation,” Science Advances 7, no. 30 (2021): eabf8660, https://doi.org/10.1126/sciadv.abf8660.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.